Long-term pulmonary function testing in pediatric bronchiolitis obliterans syndrome after hematopoietic stem cell

Sophie Walther1, Eva Rettinger2, Hannah Miriam Maurer1

  • 1Division of Allergology Pulmonology and Cystic fibrosis, Department for Children and Adolescents, Goethe University, Frankfurt, Germany.

Insights

Bronchiolitis obliterans syndrome (BOS) is rare in children after stem cell transplants but can cause severe lung issues. Despite risks, some children show lung growth, though mortality remains high.

Area of Science:

  • Pediatric Pulmonology
  • Hematology
  • Transplantation Medicine

Background:

  • Bronchiolitis obliterans syndrome (BOS) is a severe airway inflammation causing bronchiolar obstruction.
  • Long-term pulmonary outcomes in pediatric BOS post-hematopoietic stem cell transplantation (HSCT) are understudied.

Purpose of the Study:

  • To determine the incidence and long-term outcomes of BOS in children following allogeneic HSCT.
  • To characterize the patterns of lung function impairment and recovery in pediatric BOS patients.

Main Methods:

  • Retrospective analysis of 526 pediatric HSCT cases (2000-2017).
  • Evaluation of pulmonary function tests (spirometry, body plethysmography), lung clearance index (LCI), and high-resolution computed tomography (HRCT) in 14 identified BOS patients.

Main Results:

  • BOS occurred in 2.7% (14/526) of pediatric HSCT recipients.
  • Observed patterns included progressive decline (3 patients), persistent severe obstruction (5 patients), and complete recovery (6 patients).
  • Despite impairment, long-term forced vital capacity (FVC) indicated continued lung growth in survivors.

Conclusions:

  • Pediatric BOS post-HSCT is infrequent but associated with significant mortality and potential for persistent obstructive lung disease.
  • While lung growth continues, careful monitoring for long-term pulmonary complications is essential.
Abstract